Veru Inc. (VERU) investor relations documents from the company's IR site: 1 presentation, 12 press releases; latest deck 2026-02-26. Read in-app with summaries. First-party data.
Veru Corporate Presentation, February 2026: Veru Inc. business overview highlighting enobosarm's positive Phase 2 QUALITY trial results in obese patients on semaglutide and the Q1 2026 start of the PLATEAU Phase 2b study.
VERU overview · VERU earnings · VERU financials · VERU KPIs · VERU ownership · VERU peers · VERU filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.